- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02633982
GENERAL;GENeral Practitioners and Embolism pRevention in NVAF Patients Treated With RivAroxaban:reaL-life Evidence (GENeRAL)
Registry Study on the Effectiveness of Rivaroxaban in Patients With Non-valvular Atrial Fibrillation Managed by General Practitioners(GENERAL Study)
In atrial fibrillation patients,anticoagulant therapy with warfarin has an excellent stroke preventive. Meantime,Warfarin may also increase the risk of hemorrhagic events. Considering this,warfarin is a drug which puts a great burden on patients and medical providers.
With the population aging, the number of non-valvular atrial fibrillation patients is increasing, and a necessity that not only specialist but also general practitioners. Anticoagulant therapy with warfarin is not easy for general practitioners and is not commonly used among general practioners. In such circumstances, Rivaroxaban,a new oral direct factor Xa inhibitor,has become available. Rivaroxaban is administrated once a day and exert an anti- coagulant effect soon after administration. It hardly reacts with foods or other drugs and therefore does not require regular monitoring. GENERAL study is to investigate the effectiveness of stroke and systemic embolism in non-valvular atrial fibrillation patients when it is prescribed by general practioners in real life settings.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Forventet)
Kontakter og lokationer
Studiekontakt
- Navn: Saburo Saito
- Telefonnummer: +81-6-6872-0010
- E-mail: general@jcvrf.jp
Studiesteder
-
-
Osaka
-
Suita, Osaka, Japan, 565-8565
- Rekruttering
- Japan Cardiovascular Research Foundation
-
Kontakt:
- Hisao Ogawa
- Telefonnummer: 2231 +81-6-6833-5012
- E-mail: ogawah@ncvc.go.jp
-
Ledende efterforsker:
- Hisao Ogawa, M.D.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Non-valvular atrial fibrillation patient who are prescribed Rivaroxaban by General practitioners
Exclusion Criteria:
- Patients are contraindicated for rivaroxaban
- Patients judged as inappropriate for this study by investigators
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Kohorte
- Tidsperspektiver: Fremadrettet
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Composite of symptomatic stroke (ischemic/hemorrhagic) and systemic embolism
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Major bleeding events (adapted ISTH standard)
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Non-major bleeding events(without Major Bleeding complications)
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Composite of symptomatic stroke(ischemic or hemorrhagic),systemic embolism,myocardial infarction/unstable angina pectoris and cardiovascular death
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Symptomatic stroke (ischemic or hemorrhagic)
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Symptomatic ischemic stroke
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Symptomatic hemorrhagic stroke
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Systemic embolism
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Acute myocardial infarction/unstable angina pectoris
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Cardiovascular death
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Deep vein thrombosis/pulmonary thromboembolism
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Transient ischemic attack
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Percutaneous coronary intervention /coronary artery bypass grafting
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
All cause death
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Comparison of primary outcome (composite of symptomatic stroke(ischemic/hemorrhagic) and systemic embolism) rate and Major Bleeding complications (adapted ISTH standard)rate between EXPAND study and FUSHIMI AF registry
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Adverse Event excluding hemorrhagic events
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Patients adherence related with stroke or systemic embolism
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Correlation with CHADS2 score or other risk factors and outcome events in Japanese patients who administered Rivaroxaban
Tidsramme: up to 1.5 years(max 3 years)
|
up to 1.5 years(max 3 years)
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- GENeRAL/J
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Atrieflimren
-
W.L.Gore & AssociatesAfsluttetSeptal defekt, atrialForenede Stater
-
Pusan National University HospitalIkke rekrutterer endnuHjerteimplanterbar elektronisk enhed | Atrial High Rate EpisodeKorea, Republikken
-
W.L.Gore & AssociatesAfsluttetSeptal defekt, atrialForenede Stater
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Tilmelding efter invitationKortkoblet idiopatisk ventrikulær fibrillationHolland
-
Assiut UniversityTrukket tilbageASD2 (Secundum atrial septal defekt)
-
Henry Ford Health SystemTrukket tilbage
-
Nobles Medical Technologies II IncTilmelding efter invitationForamen Ovale, Patent | Septal defekt, atrial | Septaldefekt, HjerteForenede Stater, Italien
-
HeartStitch.ComUkendtForamen Ovale, Patent | Septal defekt, atrial | Septaldefekt, HjerteForenede Stater
-
Occlutech International ABAfsluttetSecundum atrial septal defekter
-
University Hospital, Basel, SwitzerlandUniversity Hospital GreifswaldAfsluttetAtrium; Fibrillering | Arytmi AtrialTyskland, Schweiz